QuantHealth
AI software simulates clinical trials before patient enrollment to help drug developers assess study design and outcome risks.
Overview
QuantHealth builds an AI platform for simulating clinical trials before patients enroll, aiming to help life sciences teams evaluate trial designs and anticipate risks earlier in development. The company targets pharmaceutical and biotech organizations seeking to improve clinical development decisions. Its key differentiator is the use of AI-driven trial simulation as a pre-enrollment planning tool. QuantHealth raised a $45 million Series B in August 2026, bringing total disclosed funding to $45 million.
Funding History
QuantHealth Snags $45M to Simulate Clinical Trials Before Patients Ever Enroll
Frequently Asked Questions
- How much has QuantHealth raised in total?
- QuantHealth has raised a total of $45M across 1 funding round.
- Who are QuantHealth's investors?
- QuantHealth's investors include Qumra Capital.
- What does QuantHealth do?
- QuantHealth builds an AI platform for simulating clinical trials before patients enroll, aiming to help life sciences teams evaluate trial designs and anticipate risks earlier in development. The company targets pharmaceutical and biotech organizations seeking to improve clinical development decisions. Its key differentiator is the use of AI-driven trial simulation as a pre-enrollment planning tool. QuantHealth raised a $45 million Series B in August 2026, bringing total disclosed funding to $45 million.
- Where is QuantHealth headquartered?
- QuantHealth is headquartered in Tel Aviv, Israel.
Investors
Related Insights
A comprehensive analysis of Sage's funding history, investors, competitive position, and growth trajectory in the AI Healthcare space.
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.